4
Total Mentions
4
Documents
5
Connected Entities
Organization referenced in documents
EFTA00849143
. EFTA00849143 Although that is a more limited pool of patients than statins treat today, industry watchers think that ongoing studies evaluating PCSK9 inhibitors more thoroughly could lead to it becoming a standard used to treat all patients at risk of heart disease. If so, then Praluent and other
EFTA00853296
hat time works for you on the 15th so I can block it out. I'll get back to you when I hear back from the godfathers of lipoproteins, but I think the PCSK9 inhibitor is key. From: Jeffrey E. [mailto:[email protected]] Sent: Saturday, June 27, 2015 4:28 PM To: Peter Atha Subject: Re: Re: thank yo
EFTA00674918
the so-called "bad cholesterol", by as much as 60%, far more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A riv
EFTA02495247
hat time works for you on the 15th so I can block it out. I'll get back to you when I hear back from the godfathers of lipoproteins, but I think the PCSK9 inhibitor is key. From: Jeffrey E. [mailto:[email protected]] Sent: Saturday, June 27, 2015 4:28 PM To: Peter Attia Subject: Re: Re: thank y

Jeffrey Epstein
PersonAmerican sex offender and financier (1953–2019)

Amgen
OrganizationAmerican multinational biopharmaceutical company
Praluent
OrganizationPharmaceutical product

Peter Attia
PersonAmerican physician specializing in longevity medicine, author and podcast host
Regeneron
PersonSurname reference in documents